Bicycle Therapeutics (BCYC) Jefferies London Healthcare Conference 2024 summary

Key achievements and strategic direction

• Demonstrated strong differentiation of technology with improved tolerability across tumor types in 2024.

• Delivered positive data for BT8009, zelenectide (BT5528), and Nectin-4-targeted CD137 (BT7480) at ESMO, highlighting robust response rates and favorable safety.

• Advanced radiopharmaceutical pipeline with novel targets MT1-MMP and EphA2, sharing compelling first-in-human imaging data.

• Completed a successful PIPE financing, attracting high-caliber investors and strengthening capital position.

• Plans for 2025 include accelerating Nectin-4 development and expanding radiopharmaceutical efforts.

Clinical program updates and differentiation

• BT8009 showed strong efficacy and differentiated tolerability in second-line urothelial cancer, with updates outside this indication expected soon.

• Zelenectide achieved a 45% ORR and 11.1-month duration of response, outperforming antibody-based therapies and showing low rates of severe adverse events.

• Withdrawal rate due to adverse events for zelenectide is only 4%, much lower than traditional ADCs.

• Combination studies with pembrolizumab and other agents are ongoing, with year-end updates anticipated.

• Registration trial Duravelo-2 is progressing, aiming for accelerated approval with a novel design and built-in confirmatory analysis.

Market opportunity and competitive landscape

• Second-line bladder cancer market remains fragmented, with no agent exceeding 20% share, presenting opportunity for new entrants.

• First-line market is evolving, with Padcev expected to reach $2B+ in peak sales, but significant share remains for better-tolerated therapies.

• Zelenectide's differentiated safety profile could double preference share over Padcev in combination with pembrolizumab.

• Nectin-4 and EphA2 are considered high-value, broadly expressed targets, with ongoing expansion into breast, lung, and other cancers.

• ADC competitors and new Nectin agents are entering the space, increasing complexity but also validating the target.